Catalog No.
MHE26001
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a
Clonality
Monoclonal
Immunogen
Recombinant Romiplostim protein.
Target
Thrombopoietin, C-mpl ligand, ML, Megakaryocyte colony-stimulating factor, Megakaryocyte growth and development factor, MGDF, Myeloproliferative leukemia virus oncogene ligand, THPO, MGDF
Concentration
2.25 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P40225
Applications
ELISA-cap
Form
Liquid
Storage buffer
NaAc, 0.2M Arg, pH5.5
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Romiplate, Romiplostim, Nplate
Clone ID
1A430
The 'Stop TPO-RA in ITP Patients' study: Clinical and immune modulatory effects of romiplostim tapering., PMID:40384450
Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia., PMID:39852180
The Establishment of a Novel Murine Model of Immune Thrombocytopenia in Pregnancy and the Impacts of Thrombopoietin Receptor Agonist on Platelet Production., PMID:39539867
[Pharmacotherapy for aplastic anemia]., PMID:39505555
Efficacy and safety of TPO receptor agonists in treatment of ITP associated with predominantly antibody deficiencies., PMID:39348667
Peptibodies: Bridging the gap between peptides and antibodies., PMID:39142490
Idiopathic Thrombocytopenic Purpura (ITP) Complicated by a Hemorrhagic Ovarian Cyst and Hemoperitoneum: A Case Report., PMID:39130867
Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management., PMID:39105265
Acute Renal Thrombotic Microangiopathy Caused by Eltrombopag and Romiplostim in a Patient with Myelodysplastic Syndromes (MDS) and Underlying Antiphospholipid Syndrome., PMID:38984183
Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatment., PMID:38942688
Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice., PMID:38843478
Treatment patterns and outcomes among adults with immune thrombocytopenia receiving pharmaceutical second-line therapies: a retrospective cohort study using administrative claims data., PMID:38465414
Successful treatment of severe passenger lymphocyte syndrome with efgartigimod synergy., PMID:38425280
Severe thrombocytopenia associated to bevacizumab in a patient with scleroderma, gastrointestinal angiodysplasias and refractory gastrointestinal bleeding., PMID:38358904
Concomitant presentation of thrombotic thrombocytopenic purpura, immune thrombocytopenia, and autoimmune hemolytic anemia in a patient with newly diagnosed systemic lupus erythematosus., PMID:38170038
Population Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim Biosimilar GP40141 and Reference Product in Healthy Volunteers to Evaluate Biosimilarity., PMID:38168134
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment., PMID:37985171
Thrombocytopenia Associated with Elemental Mercury Poisoning in Two Siblings - Connecticut, July 2022., PMID:37733629
United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism., PMID:37594915
Avatrombopag increased platelet count in a patient with chronic immune thrombocytopenia refractory to multiple lines of treatment., PMID:37395226
Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates., PMID:37335880
Early initiation of second-line therapy in primary immune thrombocytopenia: insights from real-world evidence., PMID:37300567
Combining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experience., PMID:37247631
Accelerated death of megakaryocytes from Wiskott-Aldrich syndrome patients., PMID:37221654
Severe immune thrombocytopenia in two patients with systemic sclerosis., PMID:36933783
Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model., PMID:36928007
Safety of romiplostim and eltrombopag for children with immune thrombocytopenia: a pharmacovigilance study of the FDA adverse event reporting system database., PMID:36803342
[Hematopoietic recovery by ASXL1-mutated clones after immune suppressive therapy in a patient with severe aplastic anemia]., PMID:36775307
Treatment of congenital thrombocytopenia and decreased collagen reactivity in G6b-B-deficient mice., PMID:36269841
Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study., PMID:36257098
Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim., PMID:36253251
Chemically modified in-vitro-transcribed mRNA encoding thrombopoietin stimulates thrombopoiesis in mice., PMID:36090760
Paraneoplastic syndromes: A focus on pathophysiology and supportive care., PMID:35916756
Pembrolizumab-Induced Acquired Amegakaryocytic Thrombocytopenia and Successful Combination Treatment With Eltrombopag, Romiplostim and Cyclosporine: A Brief Communication., PMID:35791464
Successful combination treatment with rituximab, steroid pulse therapy, plasma exchange and romiplostim for very severe TAFRO syndrome., PMID:35561254
A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia., PMID:35413092
Real-world experience of treatment with thrombopoietin receptor agonists in anti-thymocyte globulin-naïve patients with aplastic anemia: an observational retrospective analysis in a single institution., PMID:35306963
Drug-induced antiphospholipid syndrome: Analysis of the WHO international database., PMID:35114404
Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials., PMID:34962697
Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry., PMID:34638135
Treatment patterns in adults with immune thrombocytopenia before, during and after use of thrombopoietin receptor agonists: a longitudinal prescription database study from Germany., PMID:34547980
COVID-19 induced immune thrombocytopenic purpura: case report., PMID:34386543
How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment., PMID:33827138
Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review., PMID:33796239
Transplant-associated Thrombotic Microangiopathy Treated with Eculizumab and Romiplostim., PMID:33768076
UK second-line paediatric primary ITP therapy analysis., PMID:33597180
Persistent Immune Thrombocytopenia Resistant to Immunosuppressive Therapy: What Is the Way Forward?, PMID:33527058
Comparative Utilization and Efficacy of Thrombopoietin Receptor Agonists in Relapsed/Refractory Immune Thrombocytopenia., PMID:33491968
Therapy for lower-risk MDS., PMID:33275714
Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia., PMID:33249935
For research use only. Not for human or drug use.
